EUROPEAN BIOTECHNOLOGY | CARB-X has added six new accelerator partners to its Global Accelerator Network to increase support for development research projects it funds to fight the rise of drug-resistant bacteria. The new accelerators located in the US, Denmark, Switzerland, Germany, UK and India  join CARB-X’s existing accelerator partners, CLSI, MassBio and RTI International in the US and the Wellcome Trust in the UK to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The new accelerator partners are BaselArea.Swiss, BioInnovation Institute (BII), Centre for Cellular and Molecular Platforms (C-CAMP), Foundation for Innovative New Diagnostics (FIND), German Center for Infection Research (DZIF), and Institute for Life Sciences Entrepreneurship (ILSE).